Shield Therapeutics in demand following Canadian iron deficiency drug deal
Shares in Shield Therapeutics (STX:AIM) skipped ahead by 3.2% to 48.5p after the specialty biotech inked an exclusive licence agreement for its Accrufer oral iron deficiency drug with Canadian private company KYE...
05 January 2022